196 related articles for article (PubMed ID: 30105796)
1. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis.
Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N
J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796
[TBL] [Abstract][Full Text] [Related]
2. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells.
Chen Y; Hui H; Yang H; Zhao K; Qin Y; Gu C; Wang X; Lu N; Guo Q
Blood; 2013 May; 121(18):3682-91. PubMed ID: 23487022
[TBL] [Abstract][Full Text] [Related]
3. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.
Huang Y; Fang J; Lu W; Wang Z; Wang Q; Hou Y; Jiang X; Reizes O; Lathia J; Nussinov R; Eng C; Cheng F
Cell Chem Biol; 2019 Aug; 26(8):1143-1158.e6. PubMed ID: 31178408
[TBL] [Abstract][Full Text] [Related]
4. Wogonoside inhibits angiogenesis in breast cancer via suppressing Wnt/β-catenin pathway.
Huang Y; Zhao K; Hu Y; Zhou Y; Luo X; Li X; Wei L; Li Z; You Q; Guo Q; Lu N
Mol Carcinog; 2016 Nov; 55(11):1598-1612. PubMed ID: 26387984
[TBL] [Abstract][Full Text] [Related]
5. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
6. PLSCR1/IP3R1/Ca
Li H; Xu J; Zhou Y; Liu X; Shen LE; Zhu YU; Li Z; Wang X; Guo Q; Hui H
Cell Death Dis; 2017 May; 8(5):e2768. PubMed ID: 28492556
[TBL] [Abstract][Full Text] [Related]
7. Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction.
Chen Y; Lu N; Ling Y; Gao Y; Wang L; Sun Y; Qi Q; Feng F; Liu W; Liu W; You Q; Guo Q
Toxicology; 2009 May; 259(1-2):10-7. PubMed ID: 19428938
[TBL] [Abstract][Full Text] [Related]
8. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I
Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia in the vascular niche.
Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N
Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886
[TBL] [Abstract][Full Text] [Related]
11. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
12. Wogonoside exerts growth-suppressive effects against T acute lymphoblastic leukemia through the STAT3 pathway.
Xiao R; Gan M; Jiang T
Hum Exp Toxicol; 2017 Nov; 36(11):1169-1176. PubMed ID: 27941168
[TBL] [Abstract][Full Text] [Related]
13. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
[TBL] [Abstract][Full Text] [Related]
14. Wogonoside induces depalmitoylation and translocation of PLSCR1 and N-RAS in primary acute myeloid leukaemia cells.
Li H; Yu X; Liu X; Hu P; Shen L; Zhou Y; Zhu Y; Li Z; Hui H; Guo Q; Xu J
J Cell Mol Med; 2018 Apr; 22(4):2117-2130. PubMed ID: 29377576
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic activity of the purine analog 6-thioguanine.
Presta M; Belleri M; Vacca A; Ribatti D
Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling.
Lu J; Dong Q; Zhang S; Feng Y; Yang J; Zhao L
Cancer Sci; 2023 Aug; 114(8):3287-3300. PubMed ID: 37272257
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
18. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
19. Direct inhibition of human acute myeloid leukemia cell growth by IL-12.
Ferretti E; Di Carlo E; Cocco C; Ribatti D; Sorrentino C; Ognio E; Montagna D; Pistoia V; Airoldi I
Immunol Lett; 2010 Oct; 133(2):99-105. PubMed ID: 20705102
[TBL] [Abstract][Full Text] [Related]
20. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
